Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is an observational cohort study of virologic and immunologic outcome after at least 48
weeks of third line antiretroviral therapy. Upto 150 children at 8 Thai sites will be
enrolled. Third line antiretroviral therapy in this study is defined as an antiretroviral
(ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy
and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as
darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will
help the Thai government in planning its strategy to provide third line ARV therapy to
children within the national program.
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Ministry of Education, Thailand National Health Security Office, Thailand